These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Hindorf U; Lindqvist M; Peterson C; Söderkvist P; Ström M; Hjortswang H; Pousette A; Almer S Gut; 2006 Oct; 55(10):1423-31. PubMed ID: 16543290 [TBL] [Abstract][Full Text] [Related]
3. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity. Teich N; Mohl W; Bokemeyer B; Bündgens B; Büning J; Miehlke S; Hüppe D; Maaser C; Klugmann T; Kruis W; Siegmund B; Helwig U; Weismüller J; Drabik A; Stallmach A; J Crohns Colitis; 2016 Jan; 10(1):61-8. PubMed ID: 26468141 [TBL] [Abstract][Full Text] [Related]
4. The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study. Gensmyr-Singer H; Werner M; Karling P Therap Adv Gastroenterol; 2024; 17():17562848241228064. PubMed ID: 38384282 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Wright S; Sanders DS; Lobo AJ; Lennard L Gut; 2004 Aug; 53(8):1123-8. PubMed ID: 15247179 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of optimised thiopurine therapy in patients with moderate-to-severe ulcerative colitis: retrospective long-term follow-up from two randomised trials. Mertz Nielsen A; Theede K; Gluud LL; Kiszka-Kanowitz M Scand J Gastroenterol; 2024 Jun; 59(6):669-673. PubMed ID: 38444060 [TBL] [Abstract][Full Text] [Related]
7. Uphill battle: Innovation of thiopurine therapy in global inflammatory bowel disease care. Bayoumy AB; Mulder CJJ; Ansari AR; Barclay ML; Florin T; Kiszka-Kanowitz M; Derijks L; Sharma V; de Boer NKH Indian J Gastroenterol; 2024 Feb; 43(1):36-47. PubMed ID: 38383877 [TBL] [Abstract][Full Text] [Related]
8. Treatment efficacy and safety of low-dose azathioprine in chronic active ulcerative colitis patients: A meta-analysis and systemic review. Luan ZJ; Li Y; Zhao XY; Wang L; Sun YH; Wang SY; Qian JM J Dig Dis; 2016 Oct; 17(10):652-659. PubMed ID: 27450969 [TBL] [Abstract][Full Text] [Related]
9. Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis. Niu C; Zhang J; Napel M; Boppana LKT; Anas H; Jadhav N; Dunnigan K; Okolo PI Clin Drug Investig; 2024 Jun; 44(6):371-385. PubMed ID: 38777970 [TBL] [Abstract][Full Text] [Related]
15. Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency. Deben DS; Derijks LJJ; van den Bosch BJC; Creemers RH; van Nunen A; van Bodegraven AA; Wong DR Metabolites; 2023 Oct; 13(10):. PubMed ID: 37887379 [TBL] [Abstract][Full Text] [Related]
16. A Case Report of Follicular Lymphoma in a Crohn's Disease Patient Treated With Azathioprine. Kottavadakkeel N; Farzina R; Rajaram A; Mannath S; Sunil A Cureus; 2023 Dec; 15(12):e50839. PubMed ID: 38125685 [TBL] [Abstract][Full Text] [Related]
17. Azathioprine-Induced Porto-Sinusoidal Vascular Disease Complicated with Oesophageal Varices in a Crohn's Disease Patient - Case Report. Yazaki T; Kawashima K; Ishihara S J Crohns Colitis; 2023 Oct; 17(9):1549-1551. PubMed ID: 37067251 [No Abstract] [Full Text] [Related]